India to Belgium: Anastrozole Export Trade Route

To import Anastrozole formulations into Belgium, the following approvals and registrations are necessary:

• Marketing Authorization: A valid marketing authorization is mandatory for all medicinal products entering the European Union (EU) market. Applications must be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format, encompassing comprehensive data on quality, safety, and efficacy.

• Manufacturing and Import Authorization: Entities involved in the manufacture or import of medicinal products must possess appropriate authorizations. These authorizations are contingent upon compliance with Good Manufacturing Practice (GMP) standards.

• GMP Compliance: Manufacturing sites, including those outside the EU, must comply with EU GMP standards. Compliance is verified through inspections conducted by EU authorities or recognized under Mutual Recognition Agreements (MRAs).

• GMP Inspections for Indian Facilities: Indian manufacturing facilities exporting to Belgium are subject to GMP inspections by EU authorities. These inspections assess adherence to EU GMP standards and are essential for obtaining and maintaining import authorization.

Indian exporters of Anastrozole formulations must meet the following GMP certifications to supply Belgium:

• EU GMP Certification: Manufacturing facilities must comply with EU GMP standards, ensuring consistent product quality and safety.

• GMP Inspections: EU authorities conduct inspections of non-EU manufacturing sites to verify GMP compliance. Facilities that meet the standards receive GMP certificates, which are essential for exporting to the EU.

• Recent Inspections and Regulatory Actions: As of March 2026, specific details regarding recent inspections or regulatory actions against Indian pharmaceutical companies by the EMA are not publicly disclosed. However, Indian manufacturers are advised to stay informed about regulatory developments and ensure continuous compliance with EU GMP standards.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to Belgium:

• Revision of India's GMP Regulations: In January 2024, India's Ministry of Health revised its GMP regulations to align more closely with global standards, including those of the World Health Organization (WHO). The term 'Good Manufacturing Practices' was updated to 'Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.' This revision introduced elements such as a pharmaceutical quality system (PQS), quality risk management (QRM), and product quality review (PQR).

• EU GMP Guidelines Updates: In February 2026, the EMA initiated public consultations on revising GMP guidelines, including Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation). These revisions aim to reflect current industry practices and technological advancements.

Indian exporters should monitor these developments to ensure compliance with evolving regulatory standards and maintain market access to Belgium and the broader EU.

Anastrozole, an aromatase inhibitor, is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. In 2024, Belgium's import shipments of aromatase inhibitors, including Anastrozole, experienced a growth rate of 10.72% compared to the previous year, indicating an increasing demand for these medications. This demand is driven by factors such as the prevalence of breast cancer, an aging population, and comprehensive healthcare coverage. While Belgium imports a portion of its Anastrozole formulations, the country also has domestic pharmaceutical manufacturing capabilities that contribute to meeting the national demand.

Belgium applies a 0% Most-Favored-Nation (MFN) import duty rate on pharmaceutical products under HS code 30049099, which includes Anastrozole formulations. Additionally, these products are subject to the standard Value Added Tax (VAT) applicable to pharmaceuticals. There are no specific Free Trade Agreements (FTAs) between India and Belgium that affect pharmaceutical tariffs, and no anti-dumping duties are currently imposed on Anastrozole imports.

In 2024, the top countries exporting aromatase inhibitors to Belgium were China, Ireland, Austria, Singapore, and the USA. India's exports of Anastrozole formulations to Belgium amounted to $0.3 million USD, representing 0.2% of India's total Anastrozole formulation exports, indicating a modest share in Belgium's import market. Indian pharmaceutical manufacturers are known for their cost-effective production, often offering competitive pricing compared to European manufacturers. However, specific pricing comparisons between Indian Anastrozole formulations and those from other countries are not readily available.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug supply. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. As of November 2024, India had 396 facilities registered under the U.S. FDA's Generic Drug User Fee Amendments (GDUFA), the highest number globally.

Indian manufacturers have developed significant expertise in producing finished dosage forms containing Anastrozole, including tablets and capsules. This specialization allows for economies of scale, resulting in cost-effective production without compromising quality. The cost advantages are further enhanced by India's lower labor and operational expenses compared to Western countries.

The country's commitment to quality is evident in the numerous WHO-GMP and FDA-approved facilities dedicated to producing Anastrozole formulations. For instance, Akums Drugs and Pharmaceuticals operates two European GMP-certified units in Haridwar, focusing on solid oral dosage forms and parenterals. Similarly, Granules India Limited received U.S. FDA approval for its Hyderabad facility in November 2025, marking a significant milestone in expanding its finished dosage manufacturing capabilities.

When comparing Anastrozole formulations from India, China, and the European Union, several factors come into play:

• Price per Unit: Generic Anastrozole tablets from Indian manufacturers are competitively priced. For example, as of December 2025, the wholesale price for a 1 mg Anastrozole tablet was approximately $0.14605 per unit. In contrast, branded versions like ARIMIDEX were priced significantly higher, with costs exceeding $50 per tablet in the U.S. market.

• Quality Perception: Indian pharmaceutical companies have established a strong reputation for quality, with many facilities holding certifications from international regulatory bodies such as the U.S. FDA and WHO-GMP. This ensures that Anastrozole formulations meet stringent global standards.

• Regulatory Acceptance in Belgium: Belgium, as part of the European Union, recognizes certifications like EU-GMP. Indian manufacturers with such certifications can seamlessly export Anastrozole formulations to Belgium, ensuring compliance with local regulatory requirements.

• Supply Reliability Track Record: Indian pharmaceutical companies have demonstrated a consistent ability to supply Anastrozole formulations to global markets, including Belgium. The established trade routes and partnerships further enhance supply chain reliability.

The India-Belgium supply chain for Anastrozole formulations is robust, supported by substantial manufacturing capacities and advanced logistics:

• Manufacturing Capacity: Indian facilities dedicated to Anastrozole formulations are equipped with state-of-the-art technology, enabling large-scale production to meet global demand.

• Packaging and Cold Chain Capabilities: Manufacturers have invested in modern packaging solutions and cold chain logistics to ensure the stability and efficacy of Anastrozole formulations during transit.

• Regulatory Compliance Track Record: Indian pharmaceutical companies maintain a strong compliance record with international regulatory standards, ensuring the consistent quality of Anastrozole formulations.

• Capacity Constraints or Expansion Plans: Leading manufacturers are continually expanding their facilities and upgrading technologies to enhance production capacities, ensuring the ability to meet increasing global demand for Anastrozole formulations.

For Belgian buyers sourcing Anastrozole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Anastrozole formulations.

• Minimum Order Quantities (MOQs): Understand the MOQs set by Indian suppliers, which can vary based on production capacities and logistical considerations.

• Payment Terms: Familiarize yourself with common payment terms in India-Belgium pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems, to ensure supplier reliability.

• Regulatory Compliance: Ensure that the selected Indian manufacturers have the necessary EU-GMP certifications and are compliant with Belgian regulatory requirements for pharmaceutical imports.

By meticulously following these guidelines, Belgium companies can establish reliable partnerships with Indian Anastrozole manufacturers, ensuring the delivery of high-quality pharmaceutical formulations to the European market.